Template:Hormone levels with transdermal estradiol patches
Appearance
(Redirected from Template:Hormone levels with transdermal estradiol)
-
Levels of estradiol over a period of 8 days after a single application of a 50 or 100 μg/day Climara-type (Climara, Menostar, Mylan generic) once-weekly transdermal estradiol matrix patch to the abdomen and removed on day 7 in postmenopausal women.[7]
-
Levels of estradiol and estrone with application of a single 50 µg/day estradiol transdermal reservoir patch (Estraderm) in postmenopausal women.[8]
-
Estradiol level with a single 100 µg/day estradiol reservoir patch (Estraderm) with and without ethanol added in postmenopausal women.[9][10] This patch has a 3- to 4-day duration and is designed for twice-weekly application. In one group, ethanol was injected into the area between the patch and the skin on day 3.[9][10] This gave significantly higher and prolonged estradiol levels.[9][10]
-
Estradiol levels with 50 to 100 μg/day transdermal estradiol patches applied to the forearm and to the scrotum in a crossover study in 2 men with prostate cancer.[14] In 35 men treated continuously with one 100 μg/day estradiol patch scrotally, the mean estradiol level was ~500 pg/mL (range ~125–1,200 pg/mL).[14]
Template documentation
See also
References
- ^ "Prescribing Information: Vivelle (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
- ^ "Prescribing Information: VIVELLE-DOT (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
- ^ "Estradiol patch". Daily Med. U.S. National Library of Medicine.
- ^ "Climara (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
- ^ "Menostar (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
- ^ "ESTRADIOL patch". Daily Med. U.S. National Library of Medicine.
- ^ "Climara Forte". HPRA. Retrieved 22 December 2018.
- ^ Shah VP, Maibach HI (29 June 2013). Topical Drug Bioavailability, Bioequivalence, and Penetration. Springer Science & Business Media. pp. 47–50. ISBN 978-1-4899-1262-6.
- ^ a b c C. Christian; B. von Schoultz (15 March 1994). Hormone Replacement Therapy: Standardized or Individually Adapted Doses?. CRC Press. pp. 9–16, 60. ISBN 978-1-85070-545-1.
The mean integrated estradiol level during a full 28-day normal cycle is around 80 pg/ml.
- ^ a b c Smith RD, Robinson DE, Delignieres B, Albertson BD, Tomai TP, Zinaman MJ, Simon JA (December 1991). "Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system". Fertil. Steril. 56 (6): 1029–33. doi:10.1016/S0015-0282(16)54712-8. PMID 1743317.
- ^ Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". J. Urol. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
- ^ Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani EN, Dearnaley D, Parmar M, Abel PD (August 2008). "Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer". BJU Int. 102 (4): 442–5. doi:10.1111/j.1464-410X.2008.07583.x. PMC 2564109. PMID 18422771.
- ^ Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433. S2CID 6847203.
- ^ a b Re I, Asenjo G, Maximino G, Micheletti L (2005). "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer]. Revista Argentina de Urología (in Spanish). 70 (4): 231. ISSN 0325-2531.